Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
about
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsNovel immunotherapies for hematologic malignanciesPhenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancyLymphoma: immune evasion strategiesHarnessing the Microbiome to Enhance Cancer ImmunotherapyB and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients.T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.Murine lung cancer induces generalized T-cell exhaustion.Enterovirus-infected β-cells induce distinct response patterns in BDCA1+ and BDCA3+ human dendritic cells.The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulationMultiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancerImmunomodulatory therapy for melanoma: ipilimumab and beyondImmune based therapy for melanomaPotential targets for pancreatic cancer immunotherapeutics.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Redundant and specialized roles for diacylglycerol kinases α and ζ in the control of T cell functions.Checkpoint inhibitors in Hodgkin's lymphoma.Adoptive Cellular Therapy (ACT) for Cancer Treatment.The inducible costimulator augments Tc17 cell responses to self and tumor tissue.BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction.Mining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
P2860
Q24598792-53940A2E-9AB9-4C25-A0DB-D5BB0F02FCFFQ27004436-15198A90-63DC-4066-93A8-F64B08A219EEQ27346770-6262B9AF-05EE-47E6-8647-BCCD749C7763Q28080705-A054AA53-89D9-4A14-B9E7-2A5E048817F1Q28088598-420162CD-929B-48A1-88EA-5FA9C48AA001Q33753374-7B71DCED-93B2-432B-A3D6-6D9A57091307Q35550879-5E1A0867-F2E5-4EAB-9171-FA406303C277Q35562860-2719DB47-441D-43EA-B90B-D1A49F03523DQ35586004-656001E4-A3CA-4553-81FF-961660906362Q36053977-44256AB5-BE5A-49B5-A039-A712CBE1DE3AQ36177909-71FB6A68-02FD-497A-8471-F154F7D5BC07Q36629448-9AAD8B94-1A4C-41E5-A411-B80FCF3B5162Q36841621-DCEC30C4-D2B9-4ED3-BBFD-B888D6A44763Q36876757-AD3092DD-CC1B-49E3-96C4-256C1A56E695Q37861220-CD9D964F-30A8-4B68-981A-229A771FAE63Q38108353-A18CBC12-C3CA-4EB0-B98C-8C21ABD61270Q38374889-01F11EB9-912D-40C3-BF3C-4A7336795474Q38447171-78245FEF-5E3D-4E6E-86BC-B47EA8000757Q38631443-D0A098AF-7A8A-4EA5-8D92-2125596EDCCCQ38848219-05EB9147-0C06-4880-9319-671050DE56A6Q41551980-7CC9D367-207C-4761-BF0C-9735EEB1EE09Q41897433-14A6B1BE-3071-478C-84BE-93404EB5067AQ47774258-74DD221C-9FA7-47FC-9D48-184CB3CE7A92Q52653710-67553369-C3CD-4B63-ACE8-3EBE6EA8AC6FQ57483931-8E56949B-ECE2-43EF-80C4-227EA8CFDE81
P2860
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@ast
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@en
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
@nl
type
label
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@ast
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@en
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
@nl
prefLabel
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@ast
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@en
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
@nl
P2860
P356
P1476
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy
@en
P2093
Carl H June
Chrystal M Paulos
P2860
P356
10.1172/JCI41811
P407
P577
2009-12-28T00:00:00Z